Iridex says two-year study shows MicroPulse TLT lowers intraocular pressure in early-to-advanced glaucoma

• IRIDEX highlighted publication of a two-year independent retrospective study on MicroPulse transscleral laser therapy for primary glaucoma.
• Results were presented as already published in the International Journal of Ophthalmology, not flagged for a future medical meeting.
• Study reported sustained eye-pressure control with a lower reliance on medications across early to advanced disease stages.
• Outcomes indicated high treatment success with no reported safety issues or vision loss during follow-up.
• Findings support positioning MicroPulse TLT earlier in the glaucoma treatment pathway, potentially expanding the addressable market for Cyclo G6 systems.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120700PRIMZONEFULLFEED9843577) on October 12, 2026, and is solely responsible for the information contained therein.